RT Journal Article
SR Electronic
T1 Secondary drug resistance during an intravenous intermittent chemotherapy in newly cases TB
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP p2619
VO 38
IS Suppl 55
A1 Tatyana Petrenko
A1 Vladimir Krasnov
YR 2011
UL http://erj.ersjournals.com/content/38/Suppl_55/p2619.abstract
AB The purpose: To study frequency secondary drug resistance M. tuberculosis (SDR) during an intravenous (IV) intermittent chemotherapy in newly cases TB.Methods: 76 pulmonary TB patients without previous chemotherapy enrolled in study. IV intermittent chemotherapy (3 times a week) appointed to 38 patients (IIC-group): isoniazid (H) and rifampicin (R) – 10 mg/kg IV, streptomycin (S) – 16 mg/kg intramuscularly (IM), pyrazinamide (Z) – 25 mg/kg per os. 38 patients received daily same doses of H, R, Z per os and S IM (a group of comparison). Both groups were identical. We determined SDR initially and every 2 month of patient treatment during 5-14 months.Results: Initially there were 16 patients IIC-group and 11 in a comparison group with fully sensitive TB. In IIC-group there were 6 patients with primary MDR and 16 with primary drug resistance (not the combination of H&R). In comparison group there were 4 patients with primary MDR, and 23 with primary drug resistance. During chemotherapy 36 patients IIC-group and 34 from comparison group became sputum negative after 3,17±0,4 and 2,7±0,5 months accordingly (p=0,17, Mann-Whitney U-test). During the IV intermittent chemotherapy SDR appeared at 5 patients, secondary MDR – at 1 from 5. In comparison group SDR appeared at 4 patients, secondary MDR at 3 from 4 (RR = 1,54, 95%CI: 1,34–1,75). The mean term of formation SDR appeared in 3±0,3 and 2±0 months accordingly (p = 0,03, Mann-Whitney U-test).Conclusion: The occurrence risk of secondary MDR is lowered, SDR term is slower in IIC-group than in group of daily treatment, in about 3 months from the start of chemotherapy. This term coincides with sputum negative results at patients of both groups.